Retatrutide
Retatrutide 20mg is the higher-strength presentation of this investigational triple-receptor agonist studied at GLP-1, GIP and glucagon receptors.
Research overview
Retatrutide is a single peptide engineered to activate the GIP, GLP-1 and glucagon receptors. The 20mg compound is a higher-strength research presentation; the underlying molecule and research literature are the same as for other retatrutide presentations.
Evidence status
Retatrutide has progressed into human clinical development. Published studies include early- and mid-stage trials, while longer-term efficacy and safety questions remain under active investigation.
Areas under investigation
- Triple agonism across GIP, GLP-1 and glucagon receptors
- Energy-balance and metabolic signalling
- Body-composition and cardiometabolic research
Explore the scientific literature
For primary-source reading, search the indexed biomedical literature and registered clinical studies. These links are provided as research gateways rather than endorsements of any particular finding.